Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: Mirati Therapeutics, Inc

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.